National Medical Insurance Bureau: Expand payment channels for Innovative Drugs and guide benefit-oriented commercial health Insurance to include Innovative Drugs in the coverage responsibilities.

On January 9, 2024, the National Healthcare Security Administration held a symposium to support the development of Innovative Drugs, communicating with several pharmaceutical companies about the progress of Innovative Drugs and listening to their opinions and suggestions regarding support from the healthcare insurance department.

Zhitong FinanceJan 13 11:17

China Securities Co.,Ltd.: An outlook on the pharmaceutical Industry 2024 annual report.

In 2025, the Industry is expected to achieve moderate growth and overall move towards high-quality development.

Zhitong FinanceJan 13 09:37

Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.

The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.

Zhitong FinanceJan 10 10:20

Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.

Track the entire lifecycle of the main sector.

cls.cnJan 7 09:20

Grand Pharmaceutical's Liver Cancer Treatment Study Enrols First Patient

MT NewswiresJan 3 11:51

GRANDPHARMA (00512.HK): The registration clinical study of a Global innovative temperature-sensitive embolic agent in China has completed the enrollment of the first patient.

On January 2, Gelonghui reported that GRANDPHARMA (00512.HK) announced that the Group's Global innovative temperature-sensitive embolic agent product GPN00289 has recently completed the enrollment of the first patient in the registration clinical study conducted in China for primary liver cancer transarterial chemotherapy embolization. This study is a prospective, multi-center, randomized, parallel-controlled clinical study aimed at assessing the safety and efficacy of GPN00289 for transarterial chemotherapy embolization in primary liver cancer. The completion of the enrollment of the first patient in the registration clinical study of GPN00289 marks the Group's advancements in the field of nuclear medicine for tumor diagnosis and treatment in the direction of interventional oncology.

Gelonghui FinanceJan 2 17:06